caplacizumab - Výsledky vyhľadávania

Európska únia - slovenčina - EMA (European Medicines Agency)

cablivi

ablynx nv - caplacizumab - purpura, thrombotic trombocytopenická - antitrombotické činidlá - cablivi je indikovaný na liečbu dospelých zažíva epizóda získané thrombotic trombocytopenická purpura (attp), v spojení s plazmovou výmenu a imunosupresiu.

Európska únia - slovenčina - EMA (European Medicines Agency)

natalizumab elan pharma

elan pharma international ltd. - natalizumab - crohnova choroba - immunostimulants, - ošetrenie mierne až ťažkou aktívnou crohnovou chorobou na zníženie príznakov a symptómov, a vyvolanie a udržiavanie dlhodobého odpoveď a odpustenie, u pacientov, ktorí nereagovali a to aj napriek úplné a primerané priebehu terapie s kortikosteroidov a imunosupresívnych; alebo netolerujú, alebo majú zdravotné kontraindikácie pre takéto terapie.

Európska únia - slovenčina - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresíva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Európska únia - slovenčina - EMA (European Medicines Agency)

tysabri

biogen netherlands b.v. - natalizumab - roztrúsená skleróza - selektívne imunosupresíva - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 a 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Európska únia - slovenčina - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetylfumarát - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.